The Role of NF-κB in PPARα-Mediated Hepatocarcinogenesis by Glauert, Howard P. et al.
University of Kentucky
UKnowledge
Graduate Center for Nutritional Sciences Faculty
Publications Nutritional Sciences
1-29-2009
The Role of NF-κB in PPARα-Mediated
Hepatocarcinogenesis
Howard P. Glauert
University of Kentucky, hglauert@uky.edu
Karen Calfee-Mason
Western Kentucky University
Yixin Li
Applied Biosystems
Vani Nilakantan
Medical College of Wisconsin
Michelle L. Twaroski
Food and Drug Administration
See next page for additional authors
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/nutrisci_facpub
Part of the Nutrition Commons, and the Oncology Commons
This Article is brought to you for free and open access by the Nutritional Sciences at UKnowledge. It has been accepted for inclusion in Graduate
Center for Nutritional Sciences Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact
UKnowledge@lsv.uky.edu.
Repository Citation
Glauert, Howard P.; Calfee-Mason, Karen; Li, Yixin; Nilakantan, Vani; Twaroski, Michelle L.; Tharappel, Job; and Spear, Brett T., "The
Role of NF-κB in PPARα-Mediated Hepatocarcinogenesis" (2009). Graduate Center for Nutritional Sciences Faculty Publications. 4.
https://uknowledge.uky.edu/nutrisci_facpub/4
Authors
Howard P. Glauert, Karen Calfee-Mason, Yixin Li, Vani Nilakantan, Michelle L. Twaroski, Job Tharappel, and
Brett T. Spear
The Role of NF-κB in PPARα-Mediated Hepatocarcinogenesis
Notes/Citation Information
Published in PPAR Research, v. 2008, 286249.
© 2008 Howard P. Glauert et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided
the original work is properly cited.
Digital Object Identifier (DOI)
http://dx.doi.org/10.1155/2008/286249
This article is available at UKnowledge: https://uknowledge.uky.edu/nutrisci_facpub/4
Hindawi Publishing Corporation
PPAR Research
Volume 2008, Article ID 286249, 9 pages
doi:10.1155/2008/286249
Review Article
The Role of NF-κB in PPARα-Mediated Hepatocarcinogenesis
Howard P. Glauert,1 Karen Calfee-Mason,2 Yixin Li,3 Vani Nilakantan,4 Michelle L. Twaroski,5
Job Tharappel,1 and Brett T. Spear6
1 Graduate Center for Nutritional Sciences, University of Kentucky, Lexington, KY 40536, USA
2 College of Health and Human Services, Western Kentucky University, Bowling Green, KY 42101, USA
3 Applied Biosystems, Foster City, CA 94404, USA
4 Division of Transplant Surgery, Kidney Disease Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA
5 Food and Drug Administration, CFSAN/OFAS/DFCN, College Park, MD 20740, USA
6 Department of Microbiology, Immunology, and Molecular Genetics, University of Kentucky, Lexington, KY 40536, USA
Correspondence should be addressed to Howard P. Glauert, hglauert@uky.edu
Received 30 May 2008; Revised 3 October 2008; Accepted 3 November 2008
Recommended by Dipak Panigrahy
In this review, the role of NF-κB in the induction of hepatocarcinogenesis by peroxisome proliferators is examined. The
administration of peroxisome proliferators for more than a three-day period leads to the activation of NF-κB in the livers
of rats and mice. On the other hand, peroxisome proliferator activated receptor-α (PPARα) activation in non-hepatic tissues
can lead to the inhibition of NF-κB activation. Several lines of evidence support the hypothesis that the activation of NF-κB
by peroxisome proliferators in the liver is mediated by oxidative stress. The role of NF-κB in peroxisome proliferator-induced
hepatocarcinogenesis has been examined using NF-κB knockout models. Specifically, the induction of cell proliferation and the
promotion of liver carcinogenesis are inhibited in mice lacking the p50 subunit of NF-κB. Overall, the activation of NF-κB appears
to be important in the carcinogenic activity of peroxisome proliferators.
Copyright © 2008 Howard P. Glauert et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Peroxisome proliferators (also known as PPARα agonists) are
a group of chemically distinct compounds capable of elic-
iting persistent peroxisome proliferation in hepatocytes and
inducing liver tumors in rats andmice [1, 2]. These chemicals
activate the peroxisome proliferator-activated receptor α
(PPARα) which is essential for the carcinogenic properties
of these agents [3]. The administration of peroxisome
proliferators increases the size and number of peroxisomes
and activates genes encoding several enzymes of the peroxi-
somal β-oxidation pathway [4, 5]. The rate-limiting enzyme
of this pathway, fatty acyl CoA oxidase (FAO), produces
hydrogen peroxide (H2O2) as a by-product. In addition, the
induction of cytochrome P450 4A enzymes by peroxisome
proliferators, which is mediated through PPARα, produces
superoxide anions as by-products [6]. Oxidative stress may
be important in the toxicity and carcinogenicity of peroxi-
some proliferators, via the induction of lipid peroxidation,
oxidative DNA damage, and/or changes in gene expression
[1, 7]. The changes in gene expression may be brought about
in part by the activation of the transcription factor NF-
κB, which is known to be induced by oxidative stress. In
this review, we will discuss the evidence that peroxisome
proliferators activate NF-κB, whether NF-κB activation is
necessary for the induction of carcinogenesis by peroxisome
proliferators, and the mechanisms by which peroxisome
proliferators may influence NF-κB activation.
2. NF-κB
Nuclear factor-κB (NF-κB) is a eukaryotic transcription
factor family consisting of the following proteins: p50 (NF-
κB1), p65 (RelA), p52 (NF-κB2), c-Rel, and RelB. It is
normally found in the cytoplasm as an inactive dimer, with
the most common being the p50–p65 heterodimer, bound
to an inhibitory subunit, IκB, which also has several family
members, including IκBα, IκBβ, IκBγ, and IκBε [8]. Upon
activation, NF-κB is released from IκB and translocates to
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the nucleus, where it binds target sequences of responsive
genes. This process requires the phosphorylation of IκB,
followed by its subsequent degradation via the ubiquitin-
mediated 26S proteosome pathway [8]. A 900 kDa complex,
termed the IκB kinase (IKK) complex, has been identified
and it consists of two kinase subunits, IKKα and IKKβ,
and a regulatory subunit, IKKγ [9, 10]. These two kinase
subunits form homo- or heterodimers that phosphorylate
IκB molecules, leading to their degradation. This activation
pathway for the p50–p65 heterodimer has been referred to
as the classical or canonical NF-κB signaling pathway, and is
dependent on the IKKβ and IKKγ subunits of IKK [11]. An
alternative NF-κB signaling pathway has also been identified,
in which IKKα is required and it results in the activation of
the p52-RelB heterodimer [11].
One of the many mechanisms by which NF-κB can
be activated is by increased oxidative stress. NF-κB can
be activated in vitro by H2O2, and its activation can be
inhibited by antioxidants, such as vitamin E or N-acetyl
cysteine (NAC), or by increased expression of antioxidant
enzymes [12–18]. In addition, agents that activate NF-
κB frequently also increase oxidative stress [19]. However,
Hayakawa et al. [20] found that NAC inhibits NF-κB
activation independently of its antioxidant function.
NF-κB has been shown to be important in the reg-
ulation of numerous genes, including many that regulate
the immune response, inflammation, cell proliferation, and
apoptosis [21–23]. Several inflammatory factors that are
related to NF-κB activation have been identified, including
TNF-α, interleukin (IL)-6, and IL-1β [23, 24]. Several studies
have used genetically modified mice to examine the role
of NF-κB subunits in these functions. Knockout mice have
been developed for all NF-κB subunits [25–29]; in addition,
knockouts for specific tissues, such as the liver, have been
developed [30, 31]. Studies in which NF-κB activity has been
inhibited by the deletion of one of its subunits, the inhibition
of its translocation, or the expression of a dominant negative
form of IκB have demonstrated a clear role for NF-κB in
inhibiting apoptosis by tumor necrosis factor-α (TNF-α) or
other apoptosis inducers in several cell types [25, 26, 32–
36]. The deletion of the p65/relA subunit leads to embryonic
lethality at 15-16 days of gestation, due to hepatocyte apop-
tosis [26]. The deletion of the p50 subunit leads to defects
in the immune response involving B cells [25]. Hepatocyte
apoptosis is higher in p50 −/− mice [37, 38], but it is
not lethal as in the p65 knockout. However, DNA synthesis
and liver regeneration were not affected by the absence of
the p50 subunit following partial hepatectomy or carbon
tetrachloride treatment; increased levels of p65 may have
compensated for the lack of p50 [39]. Similarly, the hepatic-
specific expression of a truncated IκBα superrepressor did
not affect DNA synthesis, apoptosis, or liver regeneration
following partial hepatectomy, but led to increased apop-
tosis after treatment with TNF-α [40]. Also, the hepatic
inflammatory response after ischemia/reperfusion was not
altered in p50 −/− mice [41]. The deletion of p52 led
to defects in humoral immunity and splenic architecture
[28]. In RelB −/−mice, multiorgan inflammation, impaired
cellular immunity, and hematopoietic abnormalities were
observed [29]. The deletion of c-rel led to defects in humoral
immunity and in the proliferation of T cells in response to
mitogens [27]. In addition, B cells lacking p50, RelB, or c-
Rel (but not p52 or p65) exhibited decreased proliferation in
response to lipopolysaccharide (LPS) [25, 27, 42–44].
3. HEPATIC ACTIVATION OF NF-κB BY
PEROXISOME PROLIFERATORS
Our initial study examined whether peroxisome proliferators
could activate NF-κB in the liver (Table 1) [45]. Rats were
fed a diet containing 0.01% ciprofibrate; control rats received
the same diet without ciprofibrate. Animals were sacrificed
3, 6, or 10 days after starting treatment. NF-κB DNA binding
activity was monitored using electrophoretic mobility shift
assays (EMSAs) with a radiolabeled NF-κB probe. Low levels
of NF-κB were found in the liver nuclear extracts from
control rats and remained unchanged over the 10-day period.
Three days after the initiation of treatment, an increase in
nuclear NF-κB DNA binding activity was observed in treated
versus control rats. NF-κB levels continued to increase at
six and ten days after treatment. Quantitative radioanalytic
image analysis indicated that the level of induction was
nearly two-fold by day 3 and increased to 4-fold by day 10.
Hepatocyte nuclear factor 3 (HNF-3; foxa) is composed of
a family of liver-enriched transcription factors that regulate
the expression of many liver genes [46]. EMSAs with a
radiolabeled HNF-3 binding motif derived from the rat
transthyretin promoter showed that HNF-3 binding activity
remained unchanged over the 10-day period in both treated
and control rats. This indicates that ciprofibrate does not lead
to a global, but rather a more restricted increase in hepatic
transcription factor activity.
Following this initial observation, several additional
studies have demonstrated that peroxisome proliferators
activate NF-κB in the livers of rats and mice, species that
are sensitive to the carcinogenic effects of peroxisome pro-
liferators (Table 1). Ciprofibrate has been found to increase
the DNA binding activity of NF-κB in both rats and mice
[16, 17, 38, 57, 58]. Wy-14,643 and dicamba increased the
DNA binding activity of NF-κB in rats and/or mice, while
gemfibrozil and dibutyl phthalate activated NF-κB to a lesser
extent in rats and not at all timepoints [49, 53, 54, 56].
Delerive et al. [52] observed that hepatic IκBα expression was
increased by ciprofibrate in mice; this finding is somewhat
difficult to interpret since IκB is an NF-κB-regulated gene
but it is also associated with inhibiting NF-κB signaling.
Nanji et al. [55] observed that clofibrate treatment did not
affect the DNA binding activity of NF-κB (this study also
observed that clofibrate decreased ethanol-induced NF-κB
activation); however, this finding is also difficult to interpret
since all rats were fed fish oil, which itself is a peroxisome
proliferator [59]. All of the above studies examined NF-
κB activation 3 or more days after beginning peroxisome
proliferator administration. In short-term studies, Rusyn et
al. observed that hepatic NF-κB DNA binding activity was
increased shortly after a single dose of Wy-14,643, and that
the increase was primarily due to increased DNA binding
activity in Kupffer cells and to the presence of NADPH
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Table 1: Effect of peroxisome proliferators on the activation of NF-κB in the liver in vivo.
Authors Species Agent Dose Time Points Endpoint Effect
Li et al., 1996 [45] Rats Ciprofibrate 0.01% in diet 3, 6, 10 days EMSA Increased
Ohmura et al., 1996 [47] Rats BR-931
250mg/kg
single p.o.
dose
0.5–5 hr after
single dose
EMSA No effect
Menegazzi et al., 1997 [48] Rats Nafenopin
200mg/kg
single p.o.
dose
0.5–24 hr
after single
dose
EMSA No effect
Nilakantan et al., 1998 [16] Mice Ciprofibrate 0.01% in diet 21 days EMSA Increased
Espandiari et al., 1998 [49] Rats Dicamba
1 or 3% in
diet
7 days EMSA Increased
Rusyn et al., 1998 [50] Rats Wy-14,643
100mg/kg
single p.o.
dose
1–36 hr after
single dose
EMSA
Increased at 2 and
8 hr; no change at 1,
24, and 36 hr
Rusyn et al., 2000 [51] Rats Wy-14,643
100mg/kg
single p.o.
dose
2 hr after
single dose
EMSA Increased
Mice Wy-14,643
100mg/kg
single p.o.
dose
2–24 hr after
single dose
EMSA Increased
Delerive et al., 2000 [52] Mice Ciprofibrate 0.05% in diet 2 weeks IκBα expression
Increased in
wild-type but not
PPARα −/−mice
Tharappel et al., 2001 [53] Rats Wy-14,643
0.05 or
0.005% in
diet
6, 34, 90 days EMSA Increased
Gemfibrozil
0.1 or 1.6%
in diet
6, 34 days EMSA No effect
Gemfibrozil
0.1 or 1.6%
in diet
90 days EMSA
Increased only at
lower dose
Dibutyl
phthalate
0.5 or 2.0%
in diet
6 days EMSA No effect
Dibutyl
phthalate
0.5 or 2.0%
in diet
34, 90 days EMSA Increased
Hamsters Wy-14,643
0.05 or
0.005% in
diet
6, 34, 90 days EMSA No effect
Gemfibrozil
0.6 or 2.4%
in diet
6, 34, 90 days EMSA No effect
Dibutyl
phthalate
0.5 or 2.0%
in diet
6, 34, 90 days EMSA No effect
Fischer et al., 2002 [54] Rats Wy-14,643 0.1% in diet 10 days EMSA Increased
Tharappel et al., 2003 [38] Mice Ciprofibrate 0.01% in diet 10 days EMSA Increased
Calfee-Mason et al., 2004 [17] Rats Ciprofibrate 0.01% in diet 10 days EMSA Increased
Nanji et al., 2004 [55] Rats Clofibrate
100mg/kg
p.o. daily +
fish oil
4 weeks EMSA
No effect compared to
fish oil alone;
decreased
ethanol-induced
activation
Woods et al., 2007 [56] Mice Wy-14,643 0.1% in diet
1 week, 5
weeks, 5
months
EMSA
Increased in wild-type
and NADPH
oxidase-deficient
mice; no effect in
PPARα-deficient mice
Calfee-Mason et al., 2008 [57] Mice Ciprofibrate 0.01% in diet 10 days EMSA Increased
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oxidase in Kupffer cells [50, 51]. However, after a single
dose of BR-931 [47] or nafenopin [48], the DNA binding
activity of NF-κB in liver was not increased after 0.5–24 hours
following exposure. Taken together, these data suggest that
the early activation of hepatic NF-κB occurs in Kupffer cells,
while the activation in hepatocytes does not appear until 3
days or later after the beginning of peroxisome proliferator
administration. Finally, the presence of PPARα is necessary
for these changes in NF-κB activation to occur, since neither
Wy-14,643 nor ciprofibrate affected NF-κB activation in
PPARα-deficient mice [52, 56].
The activation of hepatic NF-κB had also been examined
in vitro. EMSAs demonstrated NF-κB induction by ciprofi-
brate in peroxisome proliferator-responsive H4IIEC3 rat
hepatoma cells but not in peroxisome proliferator-insensitive
HepG2 human hepatoma cell lines [18]. In addition, stably
transfectedNF-κB-regulated reporter genes were activated by
ciprofibrate in H4IIEC3 cells. These changes were observed
after 72 hours of exposure, with the increase in fatty acyl
CoA oxidase activity being observed at 24 hours, the first
time point tested. This reporter gene activation was blocked
by the antioxidants N-acetylcysteine and vitamin E. West
et al. [60] examined the activation of NF-κB in cultured
mouse hepatocytes in response to nafenopin. After a 4-
hour exposure, the DNA binding activity of NF-κB was
increased. Using human HuH7 hepatoma cells, Kleemann
et al. [61] found that Wy-14,643 increased IκBα protein
levels and decreased the nuclear translocation of NF-κB. In
addition, the peroxisome proliferatorsWy-14,643 and fenofi-
brate decreased interleukin- (IL-) 1β-induced C-reactive
protein expression. Delerive et al. [52] also found that IκBα
expression and protein levels were increased by Wy-14,643
in primary human hepatocytes and that IL-1β-induced
cyclooxygenase- (COX-) 2 protein levels were decreased by
Wy-14,643. These studies suggest that rodent hepatic NF-κB
activation is due to, at least in part, activation in hepatocytes.
In human liver cells and cell lines, however, NF-κB activation
is not affected or is decreased by peroxisome proliferator
administration.
4. IMPORTANCE OF NF-κB IN
HEPATOCARCINOGENESIS BY
PEROXISOME PROLIFERATORS
An important question is whether NF-κB activation by
peroxisome proliferators is necessary for carcinogenesis by
peroxisome proliferators, as well as the induction of changes
in cell proliferation, apoptosis, and gene expression. If NF-
κB activation does contribute to the promoting activity
of peroxisome proliferators, one would predict that if the
activity of NF-κB were diminished, the enhancement of
cell proliferation and carcinogenesis as well as the inhi-
bition of apoptosis by peroxisome proliferators would be
decreased. Several studies have examined this question,
using mice in which the p50 subunit of NF-κB has been
deleted. In the first study, the effect of p50 deletion on
cell proliferation, apoptosis, and related gene expression
was examined [38]. Wild-type and p50 −/− mice were
fed a diet with or without 0.01% ciprofibrate for 10 days.
NF-κB DNA binding activity was present and increased
after ciprofibrate treatment in wild-type mice, but was
not detected in p50 −/− mice. The untreated p50 −/−
mice had a higher level of hepatic cell proliferation, as
measured by BrdU labeling, than did untreated wild-type
mice. However, the increase in proliferation was greater
in ciprofibrate-fed wild-type mice than in ciprofibrate-fed
p50 −/− mice. The apoptotic index was low in wild-type
mice in the presence or absence of ciprofibrate. Apoptosis
was increased in untreated p50 −/− mice compared to
wild-type mice; apoptosis was reduced in p50 −/− mice
after ciprofibrate feeding. Because increased cell proliferation
in the liver is associated with increased activator protein-
1 (AP-1) activity, the expression of genes in the Fos and
Jun families of transcription factors was examined. The c-
Jun and JunB mRNA levels were higher in untreated p50
−/− mice than in untreated wild-type mice; c-Jun mRNA
levels increased whereas JunB mRNA levels decreased in
both groups after ciprofibrate treatment. However, c-Jun
and JunB protein levels were the same in untreated wild-
type and p50 −/− mice, and increased in both groups after
ciprofibrate treatment. Apoptosis-related gene expression
was also examined, and several apoptosis-related mRNAs
were higher in untreated p50 −/− mice compared to
untreated wild-typemice; expression of these genes increased
in both groups after ciprofibrate treatment. These data
indicate that NF-κB contributes to the proliferative and
apoptotic changes that occur in the liver in response to
ciprofibrate.
The role of NF-κB in the inhibition of apoptosis by
peroxisome proliferators has also been examined in vitro.
Using primary rat hepatocytes, Cosulich et al. [62] infected
cells with an adenovirus containing a dominant negative
form of IKK2. The dominant negative IKK2 induced apop-
tosis in the hepatocytes, which could not be inhibited by
the addition of nafenopin. These data indicate that NF-
κB activation is essential for the inhibition of apoptosis by
peroxisome proliferators.
The role of NF-κB in the promotion of hepatocarcino-
genesis by Wy-14,643 has been examined, using p50 −/−
mice [63]. The p50 −/− and wild-type mice were first
administered diethylnitrosamine (DEN) as an initiating
agent. Mice were then fed a control diet or a diet containing
0.05% Wy-14,643 for 38 weeks. As expected, wild-type mice
receiving DEN only developed a low incidence of tumors,
and the majority of wild-type mice receiving both DEN
and Wy-14,643 developed tumors. However, no tumors were
seen in any of the p50 −/− mice. Treatment with DEN/Wy-
14,643 increased both cell proliferation and apoptosis in
wild-type and p50 −/− mice; DEN treatment alone had no
effect. In the DEN/Wy-14,643-treated mice, cell proliferation
and apoptosis were slightly lower in the p50 −/− mice
than in the wild-type mice. These data demonstrate that
NF-κB is involved in the promotion of hepatic tumors
by the peroxisome proliferator Wy-14,643; however, in
this study, the difference in tumor incidence could not
be attributed to alterations in either cell proliferation or
apoptosis.
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5. MECHANISMS BY WHICH PEROXISOME
PROLIFERATORS INFLUENCE NF-κB ACTIVATION
The studies discussed above showed that peroxisome prolif-
erators activate hepatic NF-κB, except possibly for very short
exposure periods, and that NF-κB activation is necessary for
the promoting activity and associated biochemical activities
of peroxisome proliferators. The mechanisms by which
peroxisome proliferators activate NF-κB have been examined
in several studies. These studies can be divided into two
main groups: (1) those taking place in nonhepatic cells or
nonrodent hepatocytes, or in which the exposure time was
short; and (2) those in liver, in which the exposure time was
longer, usually greater than one week. The former studies
involved alterations in NF-κB in the absence of changes
in gene expression brought about by PPARα activation in
rodent liver. For the longer studies, however, changes in
gene expression and cell metabolism in response to PPARα
activation have occurred. These include the induction of
the peroxisomal β-oxidation pathway including fatty acyl
CoA oxidase (FAO) and the cytochrome P-450 4A (CYP4A)
family. FAO produces hydrogen peroxide as a by-product,
and CYP4A may also produce reactive oxygen species.
PPARα activation also results in a decrease in the activities of
cellular antioxidant enzymes such as glutathione peroxidase,
glutathione S-transferase, and DT-diaphorase, and in the
concentrations of cellular antioxidants such as vitamin E [7].
Therefore, oxidative stress may be an important mechanism
in the activation of NF-κB by peroxisome proliferators.
In tissues that are not responsive to the peroxisome
proliferative and carcinogenic effects to peroxisome pro-
liferators, such as human hepatocytes and nonhepatocyte
tissues and cells, the administration of PPARα activators
clearly leads to a decrease in NF-κB activation and NF-κB-
regulated gene expression. These include kidney cells in vitro
[64], human aortic smooth muscle cells [52, 65], human
HuH7 hepatoma cells [61], primary human hepatocytes
[52], human endothelial cells [66], Cos-1 cells [67], and
mouse splenocytes in vivo [68]. In these cases, PPARα
decreased NF-κB activation by the direct interaction with
p65 [65] and/or by increasing IκBα expression [52]. The
administration of peroxisome proliferators also decreased
the expression and/or protein levels of NF-κB-regulated
inflammatory genes, including IL-6 [65, 68], IL-12 [68],
C-reactive protein [61], vascular cell adhesion molecule-
1 (VCAM-1) [66], and COX-2 [67]. On the other hand,
inhibition of the NF-κB signaling pathway by inactivating
the NF-κB essential modulator (NEMO) gene in rodent liver
leads to a decrease in the expression of PPARα [69].
Several lines of evidence support the hypothesis that
NF-κB activation after one week or more of exposure to
peroxisome proliferators is mediated by oxidative stress
produced by peroxisome proliferators. First, overexpression
of the hydrogen peroxide-producing enzyme that is induced
by peroxisome proliferators, FAO, is sufficient to activate
NF-κB in Cos-1 cells [70]. In addition, FAO overexpression
in Cos-1 cells, in the presence of an H2O2-generating
substrate, can activate an NF-κB-regulated reporter gene.
Electrophoretic mobility shift assays further demonstrated
that FAO expression increases nuclear NF-κB DNA binding
activity in a dose-dependent manner. The antioxidants
vitamin E and catalase can inhibit this activation [70].
Second, overexpression of the hydrogen peroxide-
detoxifying enzyme catalase in the livers of transgenic mice
inhibits the activation of NF-κB by ciprofibrate [16]. In
this study, mice overexpressing catalase in the liver or non-
transgenic littermates were fed either 0.01% ciprofibrate or
a control diet for 21 days. FAO activity was not significantly
affected by catalase overexpression although the ratio of FAO
to catalase was significantly decreased in transgenic animals.
Ciprofibrate increased NF-κB DNA binding activity in the
livers of non-transgenic mice, but this increase was inhibited
by catalase overexpression. In addition, the ciprofibrate-
induced increase in hepatocyte proliferation was decreased
by catalase overexpression, indicating a possible role for NF-
κB in cell proliferation by peroxisome proliferators.
Third, studies in species with different responses to
peroxisome proliferators support a role for oxidative stress
in NF-κB activation. Rats and mice are sensitive to the
hepatocarcinogenic and cell proliferation-inducing effects
of peroxisome proliferators whereas other species, such as
Syrian hamsters, are not [71, 72]. Therefore, we examined the
effects of three different peroxisome proliferators on antiox-
idant enzymes, antioxidant vitamins, and NF-κB activation
in rats and Syrian hamsters [53, 73, 74]. The peroxisome
proliferators Wy-14,643, gemfibrozil, and dibutyl phthalate
were administered to animals for 6, 34, or 90 days. In
rats, decreases in glutathione reductase (GR), glutathione S-
transferase (GST), and selenium-dependent glutathione per-
oxidase (GPx) were observed following peroxisome prolifer-
ator treatment at various time points. In hamsters, a higher
basal level of activities for GR, GST, and selenium GPx was
observed as compared to rats. In addition, hamsters showed
decreases in GR and GST activities following peroxisome
proliferator treatment. Interestingly, selenium-GPx activity
was increased in hamsters following peroxisome proliferator
treatment. Treatment for 90 days with Wy-14,643 resulted
in no change in GPx1 mRNA in rats and increased GPx1
mRNA in hamsters. In both rats and hamsters treated with
Wy-14,643, we observed decreases in α-tocopherol content
and total superoxide dismutase (SOD) activity. Conversely,
DT-diaphorase activity was decreased following Wy-14,643
treatment in rats at all time points and doses, but only
sporadically affected in hamsters. Rats and hamsters treated
with DBP demonstrated increased SOD activity at 6 days;
however, in the rat, DBP decreased SOD activity at 90
days and α-tocopherol content was decreased throughout.
In gemfibrozil-treated rats and hamsters, a decrease in α-
tocopherol content and an increase in DT-diaphorase activity
were observed. In either species, no consistent trend was
observed in total ascorbic acid content after treatment with
any of the peroxisome proliferators. NF-κB activation was
evaluated by EMSA. Wy-14,643 increased the DNA binding
activity of NF-κB at all three timepoints in rats and produced
the highest activation of the three chemicals tested (Table 1).
Gemfibrozil and DBP increased NF-κB activation to a less
extent in rats and not at all times. There were no differences
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in hepatic NF-κB levels between control hamsters and ham-
sters treated with any of the peroxisome proliferators. These
studies show that NF-κB is not activated by peroxisome
proliferators in hamsters, which have much higher levels of
the antioxidant enzymes glutathione peroxidase, glutathione
S-transferase, glutathione reductase, and DT-diaphorase,
and which are not responsive to the carcinogenic effects of
the peroxisome proliferators.
Finally, the antioxidant, vitamin E, inhibits ciprofibrate-
induced NF-κB activation, both in vivo and in vitro. In
an in vitro study [18], NF-κB-regulated reporter genes
were stably transfected into rat hepatoma H4IIEC3 cells.
The ciprofibrate-induced increase in luciferase activity after
72 hours of exposure was blocked by the addition of
α-tocopheryl acetate. N-acetyl cysteine also inhibited the
ciprofibrate-induced increase. In the in vivo study [17],
thirty-six male Sprague-Dawley rats were fed a purified diet
containing varying levels of vitamin E (10, 50, 250 ppm α-
tocopheryl acetate). After 28 days, seven animals per vitamin
E group received 0.01% ciprofibrate in the diet for 10
days. Increased dietary α-tocopherol acetate inhibited CIP-
induced NF-κB DNA binding. Since NF-κB translocates to
the nucleus upon the phosphorylation and degradation of
IκB, we also used western blots to measure cytosolic protein
levels of IκBα, IκBβ, and IκB kinases: IKKα and IKKβ.
However, IκBα protein levels were decreased in all three
CIP-treated groups, with the 10 ppm vitamin E diet also
decreasing IκBα levels in control rats. No difference in IκBβ
protein levels was observed among any of the groups. The
CIP-treated rats generally had lower protein levels of IKKα
and IKKβ.
An important question is whether vitamin E is exerting
some of its effects by blocking the activation of NF-κB. The
use of NF-κB knockout models may provide answers to this
question. A study has addressed this question by examining
if the inhibition of NF-κB by vitamin E is necessary for
vitamin E’s effects on the induction of cell proliferation
by the peroxisome proliferator ciprofibrate and on the
inhibition of apoptosis by ciprofibrate [57]. Wild-type and
p50 −/− mice were administered ciprofibrate and one of
two levels of vitamin E (10 or 250mg/kg diet). Vitamin E
inhibited ciprofibrate-induced cell proliferation only in the
p50 −/− mice. Dietary vitamin E also increased apoptosis
and increased the GSH/GSSG ratio in both wild-type and
p50 −/− mice. This study suggests that vitamin E does not
act by blocking NF-κB activation, indicating that vitamin E
is acting by other molecular mechanisms.
6. CONCLUSIONS
In summary, the administration of most peroxisome pro-
liferators leads to the activation of NF-κB in the liver of
rats and mice. This activation appears to be necessary for
the tumor-promoting activity and for the induction of cell
proliferation by peroxisome proliferators. The activation
of NF-κB appears to be mediated at least in part by the
induction of oxidative stress by peroxisome proliferators.
Future studies examining the mechanisms by which NF-κB
is altered by PPARα activation will need to clearly distinguish
between those changes brought about directly by PPARα
and those brought about as a result of changes in gene
expression through PPARα (such as the peroxisomal β-
oxidation pathway). The identity of specific NF-κB-regulated
genes after the administration of peroxisome proliferators,
particularly genes related to cell proliferation and apoptosis,
will also need to be determined in future studies.
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